First Trial Group Gets Commercial Formulation of Parkinson’s Cell Therapy

A new step has been taken in the development of a potential cell-based therapy for Parkinson’s disease. Aspen Neuroscience has announced that the third group of participants in its ongoing ASPIRO clinical trial are the first to receive what the company calls the “commercial formulation” of its therapy, ANPD001. ANPD001 is designed to replace the dopamine-producing brain cells that are lost in Parkinson’s. These cells, called dopaminergic neurons, are essential for movement control and many other brain functions. Their gradual death is what leads to the classic motor symptoms of Parkinson’s, such as tremor, stiffness, and slowness. What makes Aspen’s approach different is that it’s fully personalised. Instead of using donor cells, the treatment is made from each patient’s own skin cells. These are reprogrammed into stem cells in the lab, then turned into precursor cells that can grow into dopamine-producing neurons. Once ready, the cells are frozen, shipped, and then surgically injected into the patient’s brain using Aspen’s MRI-guided precision delivery device. Because the cells come from the patient themselves, there’s no need for immune-suppressing drugs, which are often required for other kinds of cell therapy. The “commercial formulation” being used in this third group has been designed for large-scale manufacturing and consistent quality, an important step toward making the therapy practical outside of research settings. Aspen says this new version is comparable in safety and effectiveness to the earlier formulations already tested. So far, early results look promising. In the first group of trial participants, who received a lower dose, there was an average 45% reduction in motor symptom severity six months after treatment, along with a 71% improvement in daily living activities. Importantly, no serious side effects were reported, and participants did not require immune suppression. The current trial, which includes patients aged 50 to 70 who respond well to levodopa, is testing different doses to evaluate both safety and tolerability. The new commercial-ready cells are expected to simplify hospital workflows and speed up treatment, since they can be used straight from frozen. ANPD001 has also been given fast-track designation by the U.S. Food and Drug Administration, meaning regulators will work closely with Aspen and review progress more quickly than usual. While much more testing is needed before this therapy could reach wider use, the move into a commercial-ready formulation marks a major milestone. If successful, ANPD001 could become one of the first personalised, scalable cell therapies for Parkinson’s disease—offering a way not just to manage symptoms, but to directly replace the cells lost to the condition.